

Have you considered participating in a clinical research study to learn more about your cardiovascular disease and living healthily?



If you have experienced a heart attack, a stroke or you suffer from insufficient blood flow in your legs, this study may be for you

Did you know that even with the best treatments and standard of care, many people with cardiovascular disease remain at risk of suffering from a heart attack or a stroke due to build-up of fat in their blood vessels? This condition is called 'inflammation'. At the moment, no treatment exists to manage this inflammation. You may want to consider participating in the **ZEUS** study, evaluating a study drug for its ability to treat inflammation and reduce the risk of stroke, heart attack, and death, from cardiovascular causes. Join **ZEUS** in a journey of up to 4 years, with expert care, where your health is at the center.

What is the ZEUS study?

In the **ZEUS** study, we will investigate if the study medicine called 'ziltivekimab' can reduce the risk of stroke, heart attack, and death, from cardiovascular causes in people with inflammation in their blood vessels.

Can I participate in the ZEUS study?

You may qualify to participate in the **ZEUS** study if:

- You are 18 years of age or older
- You have had a stroke or heart attack, have insufficient blood flow in your legs
- Have kidney disease which does not require dialysis or a transplant
- You have diabetes
- You are able to attend regular clinic visits and receive phone calls over a period of up to 4 years

Why should I participate?

- **Join** a unique worldwide community helping to investigate the possible benefits of ziltivekimab in people like yourself
- **Learn** more about your cardiovascular or kidney disease, and how to live more healthily
- **Receive** close care and follow-up to best manage your health – where COVID-19 safety and flexibility are high priorities
- **Try** a study medication that only needs to be taken once a month by injection

This study is currently recruiting

For more information, please contact:



Saltzer
HEALTH

RESEARCH DEPARTMENT

208.463.3128

research@saltzerhealth.com

ZEUS
ziltivekimab cardiovascular
outcomes trial

Trial ID: EX6018-4758, version 1.0, date 22-Apr-2021, NA


novo nordisk®